Diffusion Pharmaceuticals is developing new drugs which help regulate the movement of oxygen into tissue by a novel mechanism of action. Because oxygen is fundamental to life’s processes, these drugs offer promising new treatments for a host of life-threatening diseases, including cancer, stroke, and heart attack. Our lead drug, trans sodium crocetinate (TSC), uses this mechanism to sensitize cancerous cells to the tumor killing power of radiation therapy.

from http://diffusionpharma.com/

Publications show all

Diffusion Pharmaceuticals has published 2 articles.

Patents show all

72Applications30Issued

Clinical Trials show all

2Phase 1/Phase 21Phase 1

SEC Filings show all

D11

Contact Information